LMR Partners’s Aspire Biopharma Warrant ASBPW Stock Holding History

LMR Partners’s Portfolio ASBPW Stock Details ASBPW Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$2.08K	Hold	125,000	–	–	﹤0.01%	1402
2025 Q4	$2.06K	Hold	125,000	–	–	﹤0.01%	1472
2025 Q3	$3.74K	Hold	125,000	–	–	﹤0.01%	1402
2025 Q2	$5.59K	Hold	125,000	–	–	﹤0.01%	1300
2025 Q1	$8.46K	Hold	125,000	–	–	﹤0.01%	1272
2024 Q4	$5.94K	Buy	+125,000	New	+$3.38K	﹤0.01%	1135
2024 Q3	–	Sell	-125,000	Closed	-$5.95K	–	1579
2024 Q2	$5.61K	Hold	125,000	–	–	﹤0.01%	1037
2024 Q1	$3.76K	Hold	125,000	–	–	﹤0.01%	1103
2023 Q4	$7.5K	Hold	125,000	–	–	﹤0.01%	878
2023 Q3	$6.34K	Hold	125,000	–	–	﹤0.01%	853
2023 Q2	$6.26K	Hold	125,000	–	–	﹤0.01%	798
2023 Q1	$1.31M	Hold	125,000	–	–	0.02%	533
2022 Q4	$1.29M	Buy	+125,000	New	+$8.4K	0.02%	630

Other funds holding ASBPW

MTCM

Mint Tower Capital Management Amsterdam, Netherlands $1.12B AUM 19.06% 1-Year Est. Return

SCM

Saba Capital Management New York $3.62B AUM 13% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

Linden Advisors New York $17.9B AUM 1.72% 1-Year Est. Return

Aristeia Capital Greenwich, Connecticut $4.82B AUM 24.94% 1-Year Est. Return

Sculptor Capital New York $9.61B AUM 27.49% 1-Year Est. Return

Toronto Dominion Bank Toronto, Ontario, Ontario, Canada $69.7B AUM 40.86% 1-Year Est. Return

Clear Street New York $24.6B AUM 56.26% 1-Year Est. Return

HCM

Highbridge Capital Management New York $3.09B AUM 31.19% 1-Year Est. Return

D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

LMR Partners's ASBPW Position: Q1 2026 in Review

LMR Partners held its Aspire Biopharma Warrant (ASBPW) position steady in Q1 2026 at 125,000 shares worth $2.08K. The position accounts for ﹤0.01% of the portfolio, ranked #1402.

LMR Partners first reported a position in ASBPW in Q4 2022 and has held it in 13 quarters since. The position peaked at $1.31M in Q1 2023. 29 funds tracked by Wall St. Rank hold ASBPW as of Q1 2026.

LMR Partners held 125,000 shares of Aspire Biopharma Warrant worth $2.08K as of Q1 2026.
LMR Partners left its Aspire Biopharma Warrant share count unchanged in Q1 2026.
Aspire Biopharma Warrant made up ﹤0.01% of LMR Partners's portfolio in Q1 2026, its #1402 holding.
LMR Partners first reported a position in Aspire Biopharma Warrant in Q4 2022 and has held it in 13 quarters since.
LMR Partners's Aspire Biopharma Warrant position peaked at $1.31M in Q1 2023.
29 funds tracked by Wall St. Rank held Aspire Biopharma Warrant as of Q1 2026.

Based on LMR Partners's 13F filing for Q1 2026, filed 15 May 2026.